Cargando…

Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers

BACKGROUND: The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a need to understand the features that make one product more 'attra...

Descripción completa

Detalles Bibliográficos
Autores principales: Butler, Stephen F, Benoit, Christine, Budman, Simon H, Fernandez, Kathrine C, McCormick, Cynthia, Venuti, Synne Wing, Katz, Nathaniel
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382206/
https://www.ncbi.nlm.nih.gov/pubmed/16457713
http://dx.doi.org/10.1186/1477-7517-3-5
_version_ 1782126843882635264
author Butler, Stephen F
Benoit, Christine
Budman, Simon H
Fernandez, Kathrine C
McCormick, Cynthia
Venuti, Synne Wing
Katz, Nathaniel
author_facet Butler, Stephen F
Benoit, Christine
Budman, Simon H
Fernandez, Kathrine C
McCormick, Cynthia
Venuti, Synne Wing
Katz, Nathaniel
author_sort Butler, Stephen F
collection PubMed
description BACKGROUND: The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a need to understand the features that make one product more 'attractive' than another to potential abusers. We developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale to measure the relative attractiveness of 14 opioid analgesic products. METHODS: First, the concept of attractiveness was empirically defined with a group of prescription opioid abusers and experts in opioid abuse using a process called Concept Mapping. Abuse liability consisted of two components: factors intrinsic to the drug formulation (e.g., speed of onset, duration) and factors extrinsic to drug formulation (e.g., availability, availability of alternatives, cost). A 17-item Opioid Attractiveness Scale (OAS) was constructed, focusing on factors intrinsic to the drug product. RESULTS: A total of 144 individuals participated in tests of validity and reliability. Internal consistency was excellent (Cronbach's α = 0.85–0.94). Drug rankings based on OAS scores achieved good inter-rater agreement (Kendall's W 0.37, p < 0.001). Agreement on drug OAS scores between the developmental sample and a confirmation sample was good (IntraClass Correlations [ICC] of 0.65–0.69). Global ratings of overall attractiveness of the 14 selected opioid products by substance abuse counselors corresponded with the rankings based on OAS ratings of the abuser group. Finally, substance abuse counselors completed the OAS, yielding a high level of correspondence with ratings by the abuser group (ICC = 0.83, p = 0.002). The OAS differentiated attractiveness among 14 selected pharmaceutical opioid products. OxyContin, Dilaudid, and Percocet were ranked highest (most attractive); Talwin NX and Duragesic were ranked lowest (least attractive). CONCLUSION: An initial examination of the psychometric properties of the OAS suggests that it is a valid and reliable scale. The OAS may be useful in providing important guidance on product features that are attractive to potential abusers.
format Text
id pubmed-1382206
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-13822062006-02-25 Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers Butler, Stephen F Benoit, Christine Budman, Simon H Fernandez, Kathrine C McCormick, Cynthia Venuti, Synne Wing Katz, Nathaniel Harm Reduct J Research BACKGROUND: The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a need to understand the features that make one product more 'attractive' than another to potential abusers. We developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale to measure the relative attractiveness of 14 opioid analgesic products. METHODS: First, the concept of attractiveness was empirically defined with a group of prescription opioid abusers and experts in opioid abuse using a process called Concept Mapping. Abuse liability consisted of two components: factors intrinsic to the drug formulation (e.g., speed of onset, duration) and factors extrinsic to drug formulation (e.g., availability, availability of alternatives, cost). A 17-item Opioid Attractiveness Scale (OAS) was constructed, focusing on factors intrinsic to the drug product. RESULTS: A total of 144 individuals participated in tests of validity and reliability. Internal consistency was excellent (Cronbach's α = 0.85–0.94). Drug rankings based on OAS scores achieved good inter-rater agreement (Kendall's W 0.37, p < 0.001). Agreement on drug OAS scores between the developmental sample and a confirmation sample was good (IntraClass Correlations [ICC] of 0.65–0.69). Global ratings of overall attractiveness of the 14 selected opioid products by substance abuse counselors corresponded with the rankings based on OAS ratings of the abuser group. Finally, substance abuse counselors completed the OAS, yielding a high level of correspondence with ratings by the abuser group (ICC = 0.83, p = 0.002). The OAS differentiated attractiveness among 14 selected pharmaceutical opioid products. OxyContin, Dilaudid, and Percocet were ranked highest (most attractive); Talwin NX and Duragesic were ranked lowest (least attractive). CONCLUSION: An initial examination of the psychometric properties of the OAS suggests that it is a valid and reliable scale. The OAS may be useful in providing important guidance on product features that are attractive to potential abusers. BioMed Central 2006-02-02 /pmc/articles/PMC1382206/ /pubmed/16457713 http://dx.doi.org/10.1186/1477-7517-3-5 Text en Copyright © 2006 Butler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Butler, Stephen F
Benoit, Christine
Budman, Simon H
Fernandez, Kathrine C
McCormick, Cynthia
Venuti, Synne Wing
Katz, Nathaniel
Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title_full Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title_fullStr Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title_full_unstemmed Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title_short Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
title_sort development and validation of an opioid attractiveness scale: a novel measure of the attractiveness of opioid products to potential abusers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1382206/
https://www.ncbi.nlm.nih.gov/pubmed/16457713
http://dx.doi.org/10.1186/1477-7517-3-5
work_keys_str_mv AT butlerstephenf developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT benoitchristine developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT budmansimonh developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT fernandezkathrinec developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT mccormickcynthia developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT venutisynnewing developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers
AT katznathaniel developmentandvalidationofanopioidattractivenessscaleanovelmeasureoftheattractivenessofopioidproductstopotentialabusers